Pausing the J&J Vaccine Was Easy. Unpausing Will Be Hard

The public health world was ready for something like this. They just didn’t know what the something would be. “When these vaccines kicked off to the world’s population, to billions of people, we knew there would be unanticipated side effects,” says Eric Topol, director of the Scripps Research Translational Institute. “These are so rare—the Johnson & Johnson one is one in a million, the AstraZeneca is one in a hundred thousand, ballpark. That’s pretty good. It doesn’t provide any solace to the one, but it should provide lots of solace to the many.”

Still, it won’t be easy to get that message across, especially when the numbers don’t yet tell the whole story. Regulators and vaccine researchers are still waiting for…

Click here to view the original article.

Related Posts